EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer

Nicole A Traphagen iD, Esmé Wheeler, Rong Li, Tara Akhshi, Ramya Ravindranathan iD, Christian Alfieri iD, Feng Lu, Buraq Ahmed, Alok K Tewari iD, Steven P Balk iD, Peter S Nelson, Eva Corey iD und 4 weitere

Proceedings of the National Academy of Sciences · 03.02.2026 · 123 (5)

DOI: 10.1073/pnas.2515790122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 27.01.2026. Verfasst von Nicole A Traphagen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Receptors, Androgen, Homologous Recombination, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCI NIH HHS, DOD | MHS | Congressionally Directed Medical Research Programs (CDMRP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatment is based on the premise that AR directly regulates expression of DNA repair genes, leading to synergy between PARP and AR inhibition. Despite some promising preclinical evidence, this combination therapy has shown limited efficacy in patients with homologous recombination (HR)–proficient tumors. To investigate this discrepancy between preclinical and clinical results, we profiled the effects of PARP inhibition in prostate cancer models in the presence or absence of AR inhibition. Surprisingly, AR inhibition impaired response to PARP inhibitors in castration-sensitive cells and had no effect on response in castration-resistant cells. AR inhibition also did not regulate DNA repair in either the castration-resistant or castration-sensitive setting. Instead, we find that cell cycle progression is required for response to PARP inhibition in homologous recombination–proficient prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsReceptors, AndrogenHomologous RecombinationProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAndrogen Receptor AntagonistsMaleHumansAnimalsCell Line, TumorMiceDNA Repair

Stichwörter der Autor:innen

PARP inhibitorandrogen receptorcastration-resistantprostate cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsReceptors, AndrogenAndrogen Receptor AntagonistsAR protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.
  • Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215.
  • Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
  • Department of Urology, University of Washington, Seattle, WA 98915.

ORCID-Profile: Nicole A Traphagen, Ramya Ravindranathan, Christian Alfieri, Alok K Tewari, Steven P Balk, Eva Corey, Alan D D'Andrea, Myles Brown

Förderung

  • NIH HHS
  • NCI NIH HHS
  • DOD | MHS | Congressionally Directed Medical Research Programs (CDMRP)
  • HHS | NIH (NIH)

Zitieren

APA

Traphagen, N. A., Wheeler, E., Li, R., Akhshi, T., Ravindranathan, R., Alfieri, C., Lu, F., Ahmed, B., Tewari, A. K., Balk, S. P., Nelson, P. S., Corey, E., Long, H., D'Andrea, A. D., Qiu, X., & Brown, M. (2026). Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer. Proceedings of the National Academy of Sciences, 123(5). https://doi.org/10.1073/pnas.2515790122

Vancouver

Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, et al. Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer. Proceedings of the National Academy of Sciences. 2026;123(5). doi:10.1073/pnas.2515790122

BibTeX
@article{Traphagen2026,
  author = {Traphagen, Nicole A and Wheeler, Esmé and Li, Rong and Akhshi, Tara and Ravindranathan, Ramya and Alfieri, Christian and Lu, Feng and Ahmed, Buraq and Tewari, Alok K and Balk, Steven P and Nelson, Peter S and Corey, Eva and Long, Henry and D'Andrea, Alan D and Qiu, Xintao and Brown, Myles},
  title = {Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {5},
  doi = {10.1073/pnas.2515790122}
}
Kostenlos starten →